The Overlooked Cost Driver in Viral Vector Manufacturing
Fixed by Your Competitors
Top-performing CDMOs have upgraded to SAN HQ and M-SAN HQ.
If you haven’t, what is it costing you?
Based on experimental data and scenario cost model, the implementation of SAN HQ or M-SAN HQ has demonstrated:
2×
Increase in Viral Vector Yield
70%
Decrease in Nuclease-Associated Costs
40%
Reduction in COGS per Dose
Viral Vector Manufacturing Is Not Just About Yield — It's About Efficiency.
In today's AAV and lentiviral vector landscape, CDMOs are under relentless pressure to:
Reduce production and QC cost
Increase batch throughput and downstream performance
Strengthen product quality and safety profile
Protect gross margins and market shares
And yet, one critical parameter remains consistently underestimated: The residual host cell DNA clearance efficiency and the nuclease strategy behind it.
The wrong nuclease strategy doesn't just affect purity.
It directly impacts cost:
Filtration Fouling
Reduced Resin Capacity
Enzyme Re-dosing
Yield Loss
In our viral vector manufacturing processes, ArcticZymes’ M-SAN HQ and SAN HQ enzymes consistently deliver efficient host-cell DNA clearance under both physiological and high-salt conditions. This has allowed us to achieve reliable digestion with fewer nuclease units, improving process efficiency without compromising quality.
Team Lead, Viral Vector Process Development at Revvity